This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Invest in Quest Diagnostics (DGX) Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) backed by its strong second-quarter performance and recovery in the base testing business.
Zacks Industry Outlook Highlights: Encompass Health, RadNet, U.S. Physical Therapy and Quest Diagnostics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Encompass Health, RadNet, U.S. Physical Therapy and Quest Diagnostics
3 Top Stocks From the Buoyant Outpatient Home Health Industry
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, rising dependence on telehealth and AI's dominant role are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. EHC, RDNT and USPH are well-poised to gain from the prospects.
Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Bet on These 3 MedTech Growth Stocks for 2021 & Beyond
by Riya Anand
Stocks like West Pharmaceutical Services (WST), IDEXX Laboratories (IDXX) and Align Technology (ALGN) make great picks for the long term.
Quest Diagnostics' (DGX) COVID-19 Test Demand Up in Q3 Months
by Zacks Equity Research
The "Path Out of the Pandemic" plan of the U.S. Government, while emphasizing more on a magnified access for testing, comes as a major breakthrough for Quest Diagnostics (DGX).
Sonos, Tencent, Quest Diagnostics, Quidel and LabCorp highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Sonos, Tencent, Quest Diagnostics, Quidel and LabCorp highlighted as Zacks Bull and Bear of the Day
3 Diagnostics Stocks in Focus on Biden's Delta Variant Mandate
by Riya Anand
Stocks like Quest Diagnostics (DGX), Quidel Corporation (QDEL) and LabCorp (LH) are the right picks now, thanks to rising COVID-19 testing demand.
Quest Diagnostic (DGX) Raises View on COVID-19 Testing Surge
by Zacks Equity Research
Going by the current situation of daily increase in the coronavirus case count, Quest Diagnostics (DGX) expects COVID-19 molecular testing volumes to remain stronger through the rest of the year.
Quest Diagnostics (DGX) Acquires Florida-Based NLS Assets
by Zacks Equity Research
Quest Diagnostics (DGX) expects the acquisition to broaden the company's spectrum in diagnostic innovation and insights.
Quest Diagnostics (DGX), eMed Deal to Boost BinaxNOW Sales
by Zacks Equity Research
Under the collaboration, eMed's Certified Guide will supervise Quest Diagnostics' (DGX) BinaxNOW home testing process virtually.
Quest Diagnostics (DGX) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
A faster-than-expected recovery in base business and stabilized demand for COVID-19 testing instill optimism in Quest Diagnostics (DGX).
Medical Device Stocks' Earnings on Jul 28: TMO, ALGN & More
by Urmimala Biswas
The sector's Q2 results are likely to reflect solid earnings and revenue growth on strong base business recovery.
Quest Diagnostics (DGX) Q2 Earnings Beat, Base Testing Strong
by Zacks Equity Research
According to Quest Diagnostics (DGX), Q2 is the first quarter since 2019 in which it has registered organic base testing revenue growth.
Quest Diagnostics (DGX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 10.80% and 6.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Quest Diagnostics (DGX) Expands Testing Access With CLX Pact
by Zacks Equity Research
Quest Diagnostics' (DGX) COVID-19 testing will be available through TrustAssure platform for international travelers and live event attendants.
Base Test Rebound to Drive Quest Diagnostics (DGX) Q2 Earnings
by Zacks Equity Research
Quest Diagnostics' (DGX) second-quarter performance within its non-COVID base business might have registered significant sales rebound.
Quest Diagnostics (DGX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Stocks in Focus on Evolving MedTech Trends Amid COVID-19
by Riya Anand
Stocks like Allscripts Healthcare Solutions (MDRX), National Vision Holdings (EYE) and Quest Diagnostics (DGX) are in focus on evolving MedTech trends.
Quest Diagnostics (DGX) Unveils Corporate Responsibility Report
by Zacks Equity Research
Per Quest Diagnostics' (DGX) 2020 Corporate Responsibility Report, it has expanded COVID-19 capacity throughout the year, performing 30 million COVID-19 molecular tests and serology tests.
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DEF
3 Medical Diagnostics Stocks in Focus on Long-Term Potential
by Riya Anand
MedTech testing stocks like Quest Diagnostics Incorporated (DGX), Thermo Fisher Scientific, Inc. (TMO) and Laboratory Corporation of America Holdings (LH) are likely to survive post-pandemic.
3 Medical Info System Stocks to Bank on Despite Decline in COVID-19 Cases
by Urmimala Biswas
The Zacks Medical Info Systems industry is gaining from growing demand for digital healthcare support. However, drop in COVID-19 cases might disrupt this uptrend. Industry players CPSI, CNTG and CERN are set to gain the most.
Quest Diagnostics (DGX) Buys Outreach Lab, Widens Midwest Base
by Zacks Equity Research
Mercy's outreach laboratory services are set to get integrated into Quest Diagnostics' (DGX) full-service laboratory in Lenexa, KS.
Quest Diagnostics (DGX) New Pact Targets Health Inequity Issue
by Zacks Equity Research
Quest Diagnostics' (DGX) new collaboration with SAHRC will help improve the health and quality of lives of underserved communities.